Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

Damian Garde In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna ...

Think different? Pharma turns to tech partnerships for beyond-the-pill moves

Tracy Staton There's not going to be a beyond-the-pill revolution in 2016. Frankly, pharma doesn't yet have the technology to move beyond pushing products to delivering outcomes. ...

With Big Pharma backing, eFFECTOR plots solid tumor trial with $40M round

John Carroll More than two years after landing a hefty launch round, San Diego-based eFFECTOR Therapeutics has scooped up a $ 40 million financing from an expanded group of investors, ...

Wings, fries and tacos come first when pharma reps order for docs

Carly Helfand It's all about Southern, American and Mexican food–at least, when pharma reps are ordering in for events at doctors' offices. FiercePharma News

Sorry, pharma. Martin Shkreli’s disgrace won’t take the heat off your pricing

Tracy Staton Pharma might think that bad boy Martin Shkreli's arrest will give the rest of the industry a breather. Though Turing Pharmaceuticals' now-ex-CEO triggered a public ...

What can Gilead, Biogen and Celgene teach Big Pharma about R&D?

John Carroll For the past 5 years the biopharma experts at Deloitte have been keeping an eye on a disturbing trend that shows no sign of letting up anytime soon. The biggest players ...

With Roche in the rear view mirror, Constellation Pharma grabs $55M round

John Carroll FierceBiotech News

In pharma M&A, 2015 trumps red-hot 2014 so far, report says

Carly Helfand Global activity in the pharma, medical and biotech spheres over the first three quarters of this year has hit its largest-to-date value since at least 2001, according ...

European pharma lobby says ‘non’ to French funding for off-label Avastin

Emily Wasserman The French government recently said "oui" to Roche's ($ RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related ...

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects ...

UPDATED: Heard the latest Kite Pharma rumor? CEO says it ain’t so

John Carroll Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. FierceBiotech News

Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes

Damian Garde A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of migraine therapy, racing to capitalize on what analysts ...
Page 2 of 1712345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS